Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging

Investigative Radiology

Volumn 42, Issue 2, 2007, Pages 105-115

  Schneider, Günther ^a   Altmeyer, Katrin ^a   Kirchin, Miles A ^b   Seidel, Roland ^a   Grazioli, Luigi ^c   Morana, Giovanni ^d   Saini, Sanjay ^e  

^a SAARLAND UNIVERSITY   (Germany)

^b Bracco Imaging SpA   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Gadobenate dimeglumine; Liver imaging; MR imaging; MR protocol

Indexed keywords

GADOBENATE DIMEGLUMINE;

ADULT; AGED; ARTICLE; CONTRAST ENHANCEMENT; ECHOGRAPHY; FEMALE; HUMAN; KAPPA STATISTICS; LIVER; LIVER CANCER; LIVER TUMOR; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

EID: 33846198771     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rli.0000251539.05400.06     Document Type: Article

References (48)

1. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol. 2006;41:213-221. Erratum in Invest Radiol. 2006;41:859.
2. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins: a new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol. 1997;32:780-796.
3. Giesel FL, von Tengg-Kobligk H, Wilkinson ID, et al. Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents. Invest Radiol. 2006;41:222-228.
4. Knopp MV, Runge VM, Essig M, et al. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology. 2004;230:55-64.
5. Knopp MV, Giesel FL, von Tengg-Kobligk H, et al. Contrast-enhanced MR angiography of the run-off vasculature: intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine. J Magn Reson Imaging. 2003;17:694-702.
6. Prokop M, Schneider G, Vanzulli A, et al. Contrast-enhanced MR angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology. 2005;234:399-408.
7. Pediconi F, Catalano C, Occhiato R, et al. Breast lesion detection and characterization at contrast-enhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine. Radiology. 2005;237:45-56.
8. Essig M, Lodemann KP, Le-Huu M, et al. Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T. Invest Radiol. 2006;41:256-263.
9. Runge VM, Biswas J, Wintersperger BJ, et al. The efficacy of gadobenate dimeglumine (Gd-BOPTA) at 3 Tesla in brain magnetic resonance imaging: comparison to 1.5 Tesla and a standard gadolinium chelate using a rat brain tumor model. Invest Radiol. 2006;41:244-248.
10. Wersebe A, Wiskirchen J, Decker U, et al. Comparison of Gadolinium-BOPTA and Ferucarbotran-enhanced three-dimensional T1-weighted dynamic liver magnetic resonance imaging in the same patient. Invest Radiol. 2006;41:264-271.
11. Schneider G, Maas R, Schultze Kool L, et al. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol. 2003;38:85-94.
12. Spinazzi A, Lorusso V, Pirovano G, et al. Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol. 1999;6:282-291.
13. Kirchin MA, Pirovano G, Spinazzi A. Gadobenate dimeglumine (gadobenate dimeglumine): an overview. Invest Radiol. 1998;33:798-809.
14. Pirovano G, Vanzulli A, Marti-Bonmati L, et al. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. AJR Am J Roengenol. 2000;175:1111-1120.
15. Kim YK, Lee JM, Kim CS. Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. Eur Radiol. 2004;14:5-13.
16. Kim YK, Kim CS, Lee YH, et al. Comparison of superparamagnetic iron oxide-enhanced and gadobenate dimeglumine-enhanced dynamic MRI for detection of small hepatocellular carcinomas. AJR Am J Roentgenol. 2004;182:1217-1223.
17. Kim YK, Lee JM, Kim CS, et al. Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol. 2005;15:220-228.
18. Spinazzi A, Lorusso V, Pirovano G, et al. MultiHance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol. 1998;5:S86-S89.
19. Caudana R, Morana G, Pirovano G, et al. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA) - preliminary results of phase II clinical application. Radiology. 1996;199:513-520.
20. Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging - a multicenter phase III clinical study. Radiology. 2000;215:727-736.
21. Grazioli L, Morana G, Federle MP, et al. Focal nodular hyperplasia: morphological and functional information from MR imaging with gadobenate dimeglumine. Radiology. 2001;221:731-739.
22. Grazioli L, Morana G, Kirchin MA, et al. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology. 2005;236:166-177.
23. Couinaud C. Le foie: études anatomiques et chirurgicales. Paris: Masson; 1957:9-12.
24. Bismuth H. Surgical anatomy and anatomical surgery of the liver. World J Surg. 1982;6:3-8.
25. Schima W, Petersein J, Hahn PF, et al. Contrast-enhanced MR imaging of the liver: comparison between Gd-BOPTA and Mangafodipir. J Magn Reson Imaging. 1997;7:130-135.
26. Baker ME, Pelley R. Hepatic metastases: basic principles and implications for radiologists. Radiology. 1995;197:329-337.
27. Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer. 1950;3:74-85.
28. Lewis KH, Chezmar JL. Hepatic metastases. Magn Reson Imaging Clin N Am. 1997;5:319-330.
29. Semelka RC, Cance WG, Marcos HB, et al. Liver metastases: comparison of current MR techniques and spiral CT during arterial portography for detection in 20 surgically staged cases. Radiology. 1999;213:86-91.
30. Semelka RC, Martin DR, Balci C, et al. Focal liver lesions: comparison of dual-phase CT and multisequence multiplanar MR imaging including dynamic gadolinium enhancement. J Magn Reson Imaging. 2001;13:397-401.
31. Sica GT, Ji H, Ros PR. Computed tomography and magnetic resonance imaging of hepatic metastases. Clin Liver Dis. 2002;6:165-179.
32. Inoue M, Sano T, Watai R, et al. Dynamic multidetector CT of breast tumors: diagnostic features and comparison with conventional techniques. AJR Am J Roentgenol. 2003;181:679-686.
33. Thibault F, Nos C, Meunier M, et al. MRI for surgical planning in patients with breast cancer who undergo preoperative chemotherapy. AJR Am J Roentgenol. 2004;183:1159-1168.
34. Schroeder T, Ruehm SG, Debatin JF, et al. Detection of pulmonary nodules using a 2D HASTE MR sequence: comparison with MDCT. AJR Am J Roentgenol. 2005;185:979-984.
35. Hamm B, Mahfouz AE, Taupitz M, et al. Liver metastases: improved detection with dynamic gadolinium-enhanced MR imaging? Radiology. 1997;202:677-682.
36. Kirchin MA, Pirovano G, Venetianer C, et al. Safety assessment of gadobenate dimeglumine (Multihance®): extended clinical experience from phase I studies to post-marketing surveillance. J Magn Reson Imaging. 2001;14:281-294.
37. Shellock FG, Parker JR, Venetianer C, et al. Safety of gadobenate dimeglumine (MultiHance): summary of findings from clinical studies and postmarketing surveillance. Invest Radiol. 2006;41:500-509.
38. Schneider G, Kirchin MA, Pirovano G, et al. Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: effect of dose on lesion detection and delineation. J Magn Reson Imaging. 2001;14:525-539.
39. Knopp MV, Bourne MW, Sardanelli F, et al. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine. Am J Roengenol. 2003;181:663-676.
40. Völk M, Strotzer M, Lenhart M, et al. Renal time-resolved MR angiography: quantitative comparison of gadobenate dimeglumine and gadopentetate dimeglumine with different doses. Radiology. 2001;220:484-488.
41. Anzalone N, Scomazzoni F, Castellano R, et al. Carotid artery stenosis: intra individual correlations of 3D time-of-flight MR angiography, contrast-enhanced MR angiography, conventional DSA, and rotational angiography for detection and grading. Radiology. 2005;236:204-213.
42. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-1917.
43. Karhunen PJ. Benign hepatic tumors and tumor-like conditions in man. J Clin Pathol. 1986;39:183-188.
44. Schwartz LH, Gandras EJ, Colangelo SM, et al. Prevalence and importance of small hepatic lesions found at CT in patients with cancer. Radiology. 1999;210:71-74.
45. Grazioli L, Morana G, Caudana R, et al. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings. Invest Radiol. 2000;35:25-34.
46. Yamashita Y, Fan ZM, Yamamoto H, et al. Spin-echo and dynamic gadolinium-enhanced FLASH MR imaging of hepatocellular carcinoma: correlation with histopathologic findings. J Magn Reson Imaging. 1994;4:83-90.
47. Hussain SM, Semelka RC, Mitchell DG. MR imaging of hepatocellular carcinoma. Magn Reson Imaging Clin N Am. 2002;10:31-52.
48. Kelekis NL, Semelka RC, Woosley JT. Malignant lesions of the liver with high signal intensity on T1-weighted MR images. J Magn Reson Imaging. 1996;6:291-294.